

Dakai Liu et al.

Serial No. 08/822,963

Filed: March 21, 1997

Page 2 (Amendment In Response to June 5, 1998 Office Action Directing
Applicants To Comply With The Sequence Rules Under 37 C.F.R. §1.821-
1.825 - March 15, 1999)


REMARKS

By this Amendment applicants are directing the entry of the substitute paper copy of the accompanying "Sequence Listing" into the instant specification, thereby conforming with one of the requirements of the Notice To Comply With Sequence Listing. Additionally enclosed herewith as Exhibit C is a Computer Readable Form of the Sequence Listing.

No fee is believed due in connection with this Amendment. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Amendment, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100

c:\uspros\enz56\amendsequence031599.ENZ56